Skip to Content
Merck
All Photos(1)

Documents

36147

Supelco

Mecoprop

PESTANAL®, analytical standard

Synonym(s):

2-(4-Chloro-2-methylphenoxy)propionic acid

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C10H11ClO3
CAS Number:
93-65-2
Molecular Weight:
214.65
Beilstein:
6568283
EC Number:
202-264-4
MDL number:
MFCD00002648
UNSPSC Code:
41116107
PubChem Substance ID:
329755294
NACRES:
NA.24

grade

analytical standard

Quality Level

100

product line

PESTANAL®

shelf life

limited shelf life, expiry date on the label

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

application(s)

agriculture
environmental

format

neat

SMILES string

CC(Oc1ccc(Cl)cc1C)C(O)=O

InChI

1S/C10H11ClO3/c1-6-5-8(11)3-4-9(6)14-7(2)10(12)13/h3-5,7H,1-2H3,(H,12,13)

InChI key

WNTGYJSOUMFZEP-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Legal Information

PESTANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

Signal Word

Danger

Hazard Statements

H302,H311,H315,H318,H410

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Eye Dam. 1 - Skin Irrit. 2

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCK2521
BCCB1112
BCBV9245
SZBE010XV
SZB9015XV

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 3

1 of 3

Novaluron PESTANAL®, analytical standard

Supelco

32419

Novaluron

Ametryn PESTANAL®, analytical standard

Supelco

45321

Ametryn

Diuron PESTANAL®, analytical standard

Supelco

45463

Diuron

Pablo J Maid et al.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 24(4), 177-182 (2017-12-13)
Biologic agents may induce immune responses that could impact drug action. The aims of this study were to assess antidrug antibodies (ADAs) in patients with rheumatoid arthritis (RA) from Argentina treated with etanercept, adalimumab, or infliximab at a single visit
Régis Peffault de Latour et al.
British journal of haematology, 191(3), 476-485 (2020-05-26)
Ravulizumab, a novel long-acting complement component 5 (C5) inhibitor administered every 8 weeks (q8w), was non-inferior to eculizumab for all efficacy outcomes in two randomised, open-label, phase 3 trials in C5 inhibitor-naïve (Study 301) and eculizumab-experienced (Study 302) adult patients
Yutaka Osuga et al.
Obstetrics and gynecology, 133(3), 423-433 (2019-02-12)
To investigate the noninferiority of relugolix compared with leuprorelin acetate in reducing heavy menstrual bleeding associated with uterine leiomyomas. In a double-blind, double-dummy trial, premenopausal women with uterine leiomyomas and heavy menstrual bleeding defined as a pictorial blood loss assessment
Julien Taieb et al.
Drugs, 79(13), 1375-1394 (2019-07-28)
The approval of targeted therapies for metastatic colorectal cancer (mCRC) has led to important improvements in patient outcomes. However, it is still necessary to increase individualisation of treatments based on tumour genetic profiles to optimise efficacy, while minimising toxicity. As
Jeffrey Vietri et al.
Human vaccines & immunotherapeutics, 16(1), 161-168 (2019-07-26)
The CDC Advisory Committee on Immunization Practices (ACIP) recommended immunization with the recently licensed 13-valent pneumococcal conjugate vaccine (PCV13) for high-risk (immunocompromised) adults aged ≥19 years in 2012. This was in addition to the 23-valent pneumococcal polysaccharide vaccine (PPSV23). Data
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service